FVB BACKGROUND

  • Model #
  • Zygosity
  • Nomenclature
  • 2767-F
    Homozygous
    FVB.129P2-Abcg2tm1Ahs N7
  • 2767-M
    Homozygous
    FVB.129P2-Abcg2tm1Ahs N7
  • Carries a disruption of the Abcg2 gene (ATP-binding cassette, sub-family G, member 2), formerly referred to as Bcrp
  • Altered drug transport capabilities due to ABC transporter protein deficiency
  • Bcrp functions as an efficient pharmacological barrier expressed in the apical membrane of epithelial cells of the small intestine, colon, cecum, and renal proximal tubules, in hepatic bile canalicular membranes, in mammary gland alveolar epithelial cells during pregnancy and lactation, and in placental labyrinth cells
  • Bcrp actively transports various anticancer drugs causing multi-drug resistance when expressed in cancer cells
  • Homozygote develops phototoxicity upon exposure to pheophorbide a, a chlorophyll metabolite, first expressed as ear lesions and can progress to mice becoming moribund
  • Homozygotes also displays a novel type of protoporphyria characterized by elevated levels of protoporphrin IX
  • Useful for studies of ATP-dependent transporters in vivo drug disposition and in inflammatory studies
 
Origin: The Bcrp mouse was developed in the laboratory of Alfred Schinkel of the Netherlands Cancer Institute in 2002. The model was created by targeting the Abcg2 gene in E14 embryonic stem cells derived from 129P2/OlaHsd mice and injecting the targeted cells into FVB blastocysts. Resultant chimeras were backcrossed to FVB/N for seven generations (N7). Taconic received stock in July 2003. The mice were derived by embryo transfer and are maintained by incrossing of homozygous mice.

Genetics: Wild type for Nnt mutation; carries Pde6brd1 mutation

Color: Albino

Initial Publication:
Jonker JW, Buitelaar M, Wagenaar E, Van Der Valk MA, Scheffer GL, Scheper RJ, Plosch T, Kuipers F, Elferink RP, Rosing H, Beijnen JH, Schinkel AH. (2002) The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci USA, 99(24):15649-54.


Conditions of Use for Taconic Transgenic Models™
Taconic Transgenic Models™ (Models) are produced and distributed under rights to patents and intellectual property licensed from various institutions. Taconic sells the Models to purchasers, grants to each purchaser a right under Taconic's rights in such licensed patents and intellectual property to use the purchased Model in consideration of purchasers' acknowledgement of and agreement to the Terms and Conditions of Sale and the following terms of use:
  • Title to these Models and biological materials derived from them remains with Taconic Biosciences, Inc.
  • The Models will be used for research purposes only.
  • The Models will not be bred except to obtain embryos or fetuses required for research purposes
  • The Models and biological materials derived from them will not be distributed to third parties or used for commercial purposes.